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SEQUENTIAL EXPOSURE TO MANGANESE AND ENCEPHALITIC VIRAL INFECTION 
CAUSES A PARKINSONIAN PHENOTYPE LIKELY MEDIATED BY ASTROGLIOSIS 
 
 
Developmental exposure to environmental toxins increases neuronal susceptibility to injury from 
subsequent viral challenges. Neurodegenerative diseases such as Parkinson’s Disease (PD) 
present with a neuroinflammatory component often linked to environmental risk factors— 
including toxic metals, chemicals, physical injury, and viral infection. While many of these risk 
factors are sufficient to cause a Parkinsonian disease state, none have been shown to be 
necessary, suggesting an underlying shared mechanism. Furthermore, for any individual risk 
factor, there is high variability regarding development and severity of the disease. One way to 
address these issues employs multiple risk factors to model the disease more accurately, although 
it is unclear how or why multiple unrelated insults have a compounding effect. 
Neuroinflammation is a shared consequence of the known environmental risk factors. Increased 
susceptibility to one insult following a challenge with another environmental toxicant may 
therefore be mediated by neuroinflammatory signaling cascades, a process largely regulated by 
glial cells, primarily astrocytes. Reactive astrocytes produce neuroinflammatory cytokines, the 
expression of which is governed by the transcription factor complex NF-κB, and its regulatory 
kinase, IKK2. The current study uses a two-hit model of environmental neurodegeneration, 
juvenile exposure to manganese (Mn) followed by adult infection with western equine 
encephalitic virus (WEEV). We found that WEEV alone produced a significant PD effect, 
evident by immunohistological staining of pathogenic markers and behavioral analyses; and that 
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WEEV and Mn exposure partially enhanced this effect. These exposures were conducted in both 
wildtype mice and in astrocyte-specific knockout mice lacking nuclear factor Ikappa-B kinase 
subunit beta (IKK-KO), hypothesizing that innate immune inflammatory signaling in reactive 
astrocytes modulates neuroinflammation and neuronal injury following combined exposure to 
Mn and WEEV. In multi-hit and single exposure treatment groups, IKK-KO mice displayed 
reduced viral replication and had decreased α-synuclein protein aggregation, astrogliosis and 
neuronal loss in multiple brain regions including the substantia nigra pars compacta, suggesting 
that astrocyte-mediated neuroinflammation may be one mechanism by which developmental 
toxin exposure can potentiate vulnerability to subsequent viral infections. Given the relevance of 
metal toxicity and viral infection to public health, these results provide insight into disease 
etiology and support further exploration of neuroinflammation as a mechanism of 
neurodegenerative pathologies. 
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Parkinson’s Disease is a progressive neurodegenerative disease without a cure or long- 
term efficacious treatments. PD affects more than 10 million people worldwide [34], and disease 
prevalence is rapidly outpacing the overall age of the population. Rates of diagnosis dramatically 
increase after age 50 [19] and the disease is 1.5 times more prevalent in men than women [34]. 
The impacts of the disease at the social and personal level are tragic, but it also carries a 
significant economic burden. It is estimated that healthcare costs for PD in the United States are 
$53 billion per year (Parkinson’s Foundation), and are expected to rise to $79 billion by 2037 
[53]. 
While the impact of the disease is variable, common symptoms include bradykinesia, 
resting tremors, impacted bowel movements, and hyposomnia [20]. Symptoms of PD worsen as 
the disease progresses and can eventually lead to death. While the disease lacks any cure, several 
treatments delay the progression. The most effective treatment is levodopa, a precursor to 
dopamine. Developed in the 1960s, levodopa addresses the symptoms caused by deteriorated 
dopamine neurons by suppling the brain with a dopamine precursor, as dopamine itself cannot 
cross the blood brain barrier [54]; treatment options based on similar principles, such as 
inhibitors of monoamine oxidase B (MAOB)—the enzyme responsible for degrading dopamine, 
have also been developed. However patients treated with these drugs require frequent increases 
in dosage over the course of the treatment, which can be effective only up to about ten years, at 
which point the frequency and dosage begin to cause severe adverse effects such as levodopa- 
induced dyskinesia [54]. The dearth of treatment options is in large part due to a lack of 
understanding of the fundamental mechanisms of the disease. 
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The molecular basis of the disease is not well understood but is characterized by several 
well-defined pathological hallmarks—including loss of dopaminergic neurons in the substantia 
nigra pars compacta, aggregation of misfolded α-synuclein protein forming Lewy bodies, and 
neuroinflammation [27]. It is unclear whether these hallmarks have a causal relationship among 
each other or the disease itself. While neuronal loss in PD occurs predominantly in the 
substantial nigra, the disease affects the circuitry of the entire basal ganglia, a region critical for 
motor behavior [51]. A potential mechanism of the disease is the misfolding of α-synuclein. The 
insoluble protein aggregate, or the soluble oligomeric form, is thought to have a neurotoxic effect 
[52], leading to selective cell death of dopaminergic neurons in the substantia nigra [49], and 
subsequent neuroinflammation surrounding the damaged tissue. Researchers pursuing the α- 
synuclein hypothesis have proposed that the disease is prion like, as treatment with pathogenic α- 
synuclein protofibrils is sufficient to induce misfolding and aggregation of the native protein 
[50]. While the α-synuclein hypothesis has provided the field with invaluable insight into the 
disease, it has nonetheless failed to explain why neuronal loss is exclusive to motor cells in the 
substantia nigra, or culminate in disease treatments. A competing hypothesis turns the model on 
its head, suggesting that neuroinflammation is the primary cause and that protein aggregation is a 
downstream effect. Neuroinflammation can trigger neuronal death by proapoptotic cytokine 
signaling (e.g. TNF- α) or by cytokine induced oxidative stress [60, 61]. While the mechanisms 
by which inflammation causes cell death are not mutually exclusive, a number of 
neuroinflammatory PD models have focused on oxidative stress pathways as many of the PD 
genetic risk factors are implicated in redox signaling [29, 30, 44]. The neuroimmune hypothesis 
holds an advantage over competing PD hypotheses in explaining the regional specificity of 
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neurodegeneration; in fact many of the environmental risk factors associated with PD have been 
shown to have selective effects on PD-relevant brain regions. 
While the central nervous system is largely considered to be immune privileged— 
protected from environmental insults by the blood-brain barrier—exposure to toxins, pollutants, 
and bacterial and viral infection have all been linked to PD [8, 33]. A prominent hypothesis that 
links environmental exposures to neurodegenerative diseases and models the stages of disease 
progression, Braak staging [4, 5], proposes that the central nervous system (CNS) is vulnerable 
to environmental exposures through both the olfactory bulb and enteric regions, finding that 
Lewy body lesions “initially occur in the dorsal motor nucleus of the glossopharyngeal and vagal 
nerves and anterior olfactory nucleus” [5]. Studies have supported this route of exposure, with 
one demonstrating that pathological alpha-synuclein travels from the gut to the brain through the 
vagus nerve [21]. 
One environmental risk factor associated with PD is viral exposure. Post-mortem 
examinations following the Spanish flu pandemic of 1918 [18] found “degenerative changes in 
the nerve cells…especially in the cells of the motor nuclei…” [47]—findings that are consistent 
with modern pathological observations of PD tissue. Other viruses that can cause Parkinsonian 
symptoms include western equine encephalitic virus (WEEV), Japanese encephalitis B (JEBV), 
and severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)—among many others [55, 
68]. While these viruses can cause motor neuron loss and behavioral phenotypes similar to PD 
patients, only WEEV has been reported to cause Lewy body formation [1, 55]. Neurological 
effects of WEEV include seizures, motor impairments, loss of taste, and intellectual disability 
[56]; the molecular effects of the disease are still poorly understood, but like other encephalitic 
infections, neuroinflammation has been observed [57]. Several patients in Colorado experienced 
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“rapid onset of postencephalitic parkinsonian sequelae,” and were subsequently treated with 
levodopa and recovered within twelve months [40]. These findings have since prompted 
researchers to use WEEV to model the disease in animals. A recent study examined the effect of 
WEEV on PD in a mouse model. The researchers infected mice with WEEV and allowed the 
mice to recover for eight weeks following infection. The researchers then examined the 
neuroinflammatory response elicited by WEEV and if these mice developed a Parkinsonian 
phenotype. They found that infection with WEEV in mice causes Parkinsonian motor 
impairments, aggregates of proteinase-K resistant alpha-synuclein and increased astrocyte 
reactivity [1, 35]. 
Another environmental exposure that has been utilized to model PD is manganese. 
Manganese is a heavy metal used in industrial applications and has been shown to be a risk 
factor in many neurological disorders [3, 23]; a Parkinsonian phenotype associated with toxic 
manganese exposure is termed manganism. Manganese causes cytotoxicity by producing 
reactive oxygen species that disrupt mitochondrial function, eventually triggering apoptotic and 
necrotic signaling cascades [58]. Manganism can be caused by inhalation or ingestion of 
manganese, and is most prominent among individuals working in industrial settings—including 
mining, welding, and fossil fuel combustion [59]. Heavy metal toxicity has been linked to many 
types of neurodegeneration, although manganese is specifically linked to PD. This relationship, 
while not fully understood, may be because manganese accumulates in the basal ganglia, and 
thus may have a selective neurotoxic effect on neurons involved in motor circuitry. 
Parkinson’s disease is also linked to several genetic risk factors, the most notable of 
which are mutations in the E3 ubiquitin ligase PARKIN [29], the mitochondrial kinase PINK1 
[30], and the LRRK2 kinase [44]. The LRRK2, leucine-rich repeat kinase 2, mutation is a 
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significant predictor of familial PD [64], and it is particularly relevant to neuroinflammatory 
models of the disease as it regulates autophagy induced by glial cells [63]. The most prominent 
pathogenic LRRK2 mutation occurs in its kinase domain, which leads to an increase in 
enzymatic activity; this increased activity disrupts a wide range of signaling cascades, including 
the mitogen-activated kinase pathway, Wnt signaling, and mitochondrial uncoupling [65]. A 
substantial component of LRRK2 dysregulation is increased glial mediated neuroinflammation, 
and it is unclear if the mutation in itself is a unique contributor to PD pathogenesis or if it is an 
alternative means to the inflammatory ends caused by environmental risk factors. 
A multi-hit model of the disease is a more physiologically relevant representation of the 
environmental exposures in one’s life that may lead to onset of the disease [32, 43]. A lingering 
question within the field is why some individuals who are exposed to manganese, or WEEV, 
develop the disease, whereas others who experience the same exposures do not? Development of 
Parkinson’s disease may be attributed to an accumulation of exposures throughout one’s life [6]. 
A biological process such as immune memory is a possible mechanism underlying such a 
compounding effect; and although this process has been historically attributed to the adaptive 
immune response, recent studies have demonstrated innate immune memory within glial cells of 
the nervous system[12, 45]. As the primary immune cells of the brain, and the central drivers of 
neuroinflammation, glial cells are an ideal target for investigating the links between Parkinson’s 
Disease and sequential exposures to environmental risk factors. 
Neuroinflammation is regulated by glial cells of the CNS, most notably astrocytes and 
microglia. Glial cells have been historically understood as simply regulators of CNS 
homeostasis, playing important roles in neurotransmitter recycling, modulating the extracellular 
milieu, and enhancing synaptic function [66]. Within the past several decades, our understanding 
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of glia has risen exponentially. Glial cells play vital roles in all the aforementioned processes, as 
well as CNS development, tissue repair, and neuroinflammation. Their function in modulating 
neuroinflammation is associated with many disease states including PD [67]. Inflammation 
induced by glial cells is caused by the release of cytokine signaling molecules, a majority of 
which are regulated by the transcription factor complex NF-κB [13]. Modulating NF-κB activity 
of glial cells has thus become a useful model in elucidating how risk factors that have a 
neuroinflammatory component contribute to diseases of the nervous system, this has become 
particularly relevant for environmental risk factors. 
The two PD risk factors, WEEV and manganese, have been shown to cause severe 
neuroinflammation [35, 39]. This study uses both manganese and WEEV exposure to model the 
progression of PD while investigating the contribution of neuroinflammation through genetic 
manipulation of glial cells. These exposures were conducted in both wildtype mice and in 
astrocyte-specific knockout mice lacking nuclear factor Ikappa-B kinase subunit beta knockout 
(IKK2-KO). IKK2 regulates NF-κB nuclear translocation by phosphorylating the NF-κB 
inhibitor IκB— which is then degraded by ubiquitination (Fig. 1). Therefore, knocking out IKK 
results in constitutive inhibition of NF-κB and the inflammatory genes it regulates. Astrocyte 
specific KO mice are ideal for interrogating the neuroimmune response and isolating the 
contribution of glial cells to particular phenotypes. NF-κB in neurons is involved in a variety of 
cellular functions—including development and synaptic homeostasis; conversely, NF-κB in glial 
cells is highly expressed only during reactive states, and is primarily implicated in inflammation 
and disease [13]. Furthermore, while NF-κB signaling in astrocytes and microglia are both 
involved in neuroinflammation, microglia are typically the first responders nervous system 
injury—often secreting factors that recruit and activate astrocytes [2]. Astrocyte inflammatory 
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signaling being downstream of other glial cells allows for a more precise interrogation of the role 
of glial cells in neuronal injury. We hypothesize that innate immune inflammatory signaling in 
reactive astrocytes modulates neuroinflammation and neuronal injury following combined 
exposure to MnCl2 and WEEV. At the study endpoint, eight weeks post-infection, mice were 
analyzed for WEEV replication, dopaminergic neuronal loss, alpha-synuclein aggregation, glial 



















Figure 1. NF-κB and IKK2 signaling cascade. IKK2 becomes active by phosphorylation. In its 
active state, IKK2 phosphorylates IκBα. Phosphorylation of IκBα leads to its ubiquitination and 
degradation. The nuclear localization signal of the heterodimer, NF-κB, becomes exposed upon 








WEEV viral replication in the CNS is enhanced by juvenile exposure to manganese 
 
A previous study [1] demonstrated that an intranasal inoculation of WEEV in wild-type 
mice propagated through olfactory bulbs, entorhinal cortex, hippocampus, ventral tegmental area 
(VTA) and substantia nigra (SN). We hypothesized that an inflammatory insult during juvenile 
stages of mouse development would potentiate a second inflammatory insult during the adult 
stages of life; specifically, we predict that the WEEV infection will be more severe in mice that 
are pretreated with MnCl2. To test this hypothesis, juvenile mice were given drinking water 
supplemented with MnCl2 (50mg/kg) for thirty days at a dose that has been shown to be 
subthreshold for primary toxic effects [31]. Mice were then aged into adulthood for another 
thirty days—and at which point were given an intranasal inoculation of WEEV. WEEV has been 
shown to be lethal in mice after four days [35], and therefore were given passive immunotherapy 
using rabbit antiserum against WEEV concurrent with infection, inoculation and dosing 
protocols were adapted from Bantle et al. 2019. Eight weeks after the cessation of MnCl2 
treatment, mice were intranasally inoculated with a dsRed-WEEV recombinant virus at a 
concentration of 1×104 PFU/ml (Fig. 2A). Mice were sacrificed 72 hours post-infection and viral 
replication was visualized by confocal microscopy. This timepoint was chosen based on prior 
findings that virus begins to clear from the brain as early as 72hr following infection. Infection 
was quantified by demarcating specific regions using the Allen Brain Atlas (Allen Mouse Brain 
Atlas 2004) and counting dsRed positive cells using Olympus Cellsens software. For each 
biological replicate (n=6), two technical replicate 10X montage images were acquired, and cell 
counts were averaged. Unpaired t-tests were performed using GraphPad Prism v9.0 comparing 
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cell counts within each region across treatment groups. The substantia nigra and hippocampus 
was quantified due to their relevance to Parkinson’s disease [48] as well as their previous 
implication in WEEV viral infection [1]. 
Consistent with previous findings, regions of the brain infected with WEEV include 
entorhinal cortex, hippocampus, VTA, and SN (Fig. 2B). As expected, the MnCl2 treatment 
group displayed an increase of dsRed positive cells (Fig 2C) in both the substantia nigra 
(P<0001) and the hippocampus (P<0.001). Further, in the MnCl2 treatment group, viral presence 
was also detected in brain regions adjacent to those previously noted; for example, in the 
Mn/WEEV condition, viral infection was not only detected in the SN and VTA, but also in the 
mamillary bodies ventral to the VTA. The same is true for cortical regions surrounding the 
entorhinal cortex. These results demonstrate successful infection of mice with dsRed-WEEV and 
replication of prior findings that used a similar treatment regimen [1, 35]. Furthermore, these 
data suggest that treatment with MnCl2 during the juvenile period does indeed potentiate the 










































Figure 2. WEEV viral spread in the CNS is enhanced by juvenile exposure to manganese. 
Experimental paradigm is described in (A), and viral constructs are shown in (B); briefly, 
juvenile mice received either standard drinking water or water supplemented with 50mg/kg 
MnCl2 for 30 days. All mice received standard drinking water for 30 days prior to inoculation 
with WEEV-dsRed or a sham vehicle inoculation. Mice were sacrificed 72hr post infection and 
examined for ds-Red expressing cells. (C) dsRed positive cells in coronal sections of mice 
receiving WEEV alone (above) or mice receiving MnCl2 and WEEV (below). Allen mouse brain 
atlas overlayed on right hemisphere for orientation, specific regions quantified (substantia nigra 
and hippocampus) are highlighted in both hemispheres. (D) dsRed positive cells in each region 
across treatment groups. Total cell counts were divided by the area of each region; each data 
point is an average of two technical replicates for each biological replicate (n=6). SN = 
substantia nigra. *** = p<0.001. 
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A key inflammatory regulator, NF-κB, affects viral infection 
 
Given the role of astrocytes in modulating the neuroimmune response [36], and the role 
of NF-κB in stimulating A1 astrocyte reactivity [24], we predict that knocking out this key 
inflammatory regulator in astrocytes will reduce replication of WEEV in both the MnCl2 
pretreatment and the WEEV alone groups. To gain insight into the role of glial-mediated 
neuroinflammation during WEEV infection, we also performed a pilot study in which we 
monitored WEEV replication at 72hr post-infection in astrocyte specific IKK2 KO transgenic 
mice using a WEEV-luciferase (WEEV-luc) recombinant virus. The WEEV-luc construct has 
been previously validated [1] and allows for live tracking of the virus during the course of the 
experiment. 
Wild-type and transgenic animals were inoculated with WEEV-luc or sham inoculated 
eight weeks after cessation of MnCl2 treatment (Fig. 3A). Seventy-two hours after inoculation 
mice were anesthetized, given a subcutaneous injection of luciferin at 150mg/kg, and imaged 
using the IVIS 200 bioluminescence imaging system. Background light emission was estimated 
from uninfected wild-type mice and subtracted from signal in WEEV infected mice. 
Contrary to previous observations, wild-type mice that received MnCl2 did not show a 
significant increase in reporter activity over mice that received WEEV alone (p=0.08; Fig. 3D); 
moreover, no effect was not observed when making the same comparison within the KO 
treatment group (p=0.12). Also contrary to our expectations, knockout of NF-κB signaling 
appeared to have no effect on viral replication, for no differences were detected between wild- 
type and KO mice. A power analysis of the experiment revealed the test is underpowered (power 
= 0.46) to detect differences between the conditions, and that a sample size of five per group 

































Figure 3. Knockout of key inflammatory regulator effects viral infection. Experimental strategy 
described in (A), and viral constructs are shown in (B). Bioluminescence of WEEV-luc mice is 
plotted in (D) as total flux (photons/s); no outliers were detected using ROUT detection in 
Graphpad Prism. Representative images of mice anesthetized with isoflurane using the XGI-8 
anesthesia system (Caliper Life Sciences, Waltham, MA USA) and imaged using the IVIS 200 
imaging system is shown in (E). Light emission is pseudo colored to represent counts of photons 
detected by CCD camera and overlayed onto mice in standard light conditions. Survival of mice 
throughout the course of the study is plotted in (C), Gehan-Breslow-Wilcoxon tests were used to 




Reactive astrocytes in the CNS after viral infection 
 
Inflammation in the nervous system is modulated by glia cells, primarily astrocytes and 
microglia [7, 9, 14]. In a reactive, or inflammatory, state, astrocytes upregulate expression of the 
intermediate filament GFAP [41]; this upregulation likely underlies concomitant morphological 
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changes that further characterize the reactive state of astrocytes [46]. Parkinsonian pathology 
instigated by sequential neuroinflammatory insults would likely be accompanied by an increase 
in the reactive astrocytosis in regions associated with PD. In our current model, it is expected 
that mice exposed to MnCl2 prior to WEEV infection will display increased astrocyte reactivity 
compared to mice receiving WEEV alone. Furthermore, it is expected that knocking out NF-κB 
in astrocytes will result in less reactivity across all treatment groups. 
Astrocyte reactivity was assessed by GFAP immunofluorescence in whole brain sections. 
 
Mice were perfused and selected tissue were fixed at P163, at eight weeks post-infection 
(n=4/treatment group). Tissue was dissected and embedded in paraffin for subsequent sectioning 
and staining. Coronal sections were stained with DAPI and monoclonal GFAP antibodies (see 
Methods) and imaged using an Olympus BX63 confocal microscope. GFAP positive cells were 
counted using Olympus Cellsens software in manually defined regions of interest. 
An analysis of the survival curves (Fig. 3C) does reveal an effect of the dual-hit 
compared to WEEV alone in wild-type mice, although it is not clear if these differences are 
associated with increased astrocyte activity. The survival curve of the knockout dual hit group 
was not statistically different from all other treatment groups, suggesting that the dual-hit effect 
is mediated by NF-κB signaling in astrocytes. 
WEEV infection alone displayed significantly higher GFAP expression compared to the 
control group in the SN (p=0.03) and cortex (p=0.04) (Fig. 4); however, no differences were 
detected within the hippocampus. Power analysis for tests within the SN and hippocampus 
revealed that this test was slightly underpowered (power = 0.43), and that increasing the sample 
size by one for each group would give more confidence in the differences observed. Mean 
differences in the hippocampus were by comparison much smaller, and thus would require a 
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dramatic increase in sample size to detect differences. Whether or not differences were observed 
in the dual-hit treatment group is unknown, for a vast majority of mice within the wt/Mn/WEEV 
treatment group did not survive the full duration of the treatment regimen (Fig. 3C). While we 
were not able to compare GFAP expression in KO/Mn/WEEV to wt/Mn/WEEV, comparisons 
between wt/H2O/WEEV and KO/H2O/WEEV were used to shed light on the relevance of 
astrocyte NF-κB signaling during WEEV infection. While mean GFAP expression levels trend 
lower in the KO group, statistical differences between the two groups were not detected in any of 
the regions examined. These results show that WEEV infection is sufficient to elicit a reactive 
phenotype in astrocytes in several brain regions, and that mice in the KO group are not 






Figure 4. Reactive astrocytes in PD-relevant brain regions. Whole brain 10X montage images 
showing GFAP in red counterstained with DAPI (A-E); corresponding sections from the Allen 
Mouse Brain Atlas is overlayed onto right hemisphere. F – G showing quantification of 
astrocytes in relevant brain regions; all counts are of single hemisphere. * = p<0.05, ** = p<0.01, 




IKK2 KO rescues behavioral deficits in mice infected with WEEV 
 
Behavioral hallmarks of Parkinson’s Disease include motor deficits such as tremors, 
bradykinesia, and imbalance [10]. To assess these clinical features in our experimental model, a 
mouse trackway system was developed to monitor movement across an enclosed glass platform 
(Fig. 5A). Mice paw pads were recorded from an upward facing camera below the platform and 
gait analysis was performed using MATlab software. Data extrapolated includes paw support, 
run duration, step size, swing speed, and swing time. More details of this trackway system are 
described in Hammond et al. 2018. 
A previous study has shown that WEEV infection causes motor deficits in mice; 
therefore, we expect that these findings will be replicated in our wild-type mice. Moreover, the 
increased severity of WEEV infection caused by MnCl2 should exacerbate these effects. Wild- 
type mice were compared against IKK2 KO mice with the prediction that knocking out 
inflammatory signaling in astrocytes will ameliorate the motor effects associated with MnCl2 and 
WEEV. 
Behavioral gait analysis was performed immediately prior to sacrifice. Mice were placed 
in the trackway system in low light conditions during mouse subjective night. Mice moved 
across the 1-meter platform towards their home cage at the end of the platform. Light was 
projected above the mice and paw prints were recorded from below the platform. Swing speed 
was measured as the speed (cm/s) of the same mouse paw starting at the initiation of movement 
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from one step to the next. Swing time was recorded as the time (s) between initiating steps, and 
run duration was the time to reach their home cage once movement in the correct direction was 
initiated. No meaningful differences were detected in swing speed; however, run duration was 
significantly higher in wild-type WEEV infected mice compared to all other treatment groups. 
(Fig 5), with the KO/H2O/WEEV and KO/Mn/WEEV being significantly lower. The two 
wt/Mn/WEEV mice that survived throughout the experimental regimen were not able to 
complete the trackway, and thus were not included in the analysis. No differences were observed 
in paw support for any group comparison (Fig. 5). These results indicate that WEEV infection 
causes Parkinsonian-like motor deficits in mice, and that these effects may be mediated by NF- 
κB signaling in astrocytes. All behavioral analyses with the exception of run duration were well 
powered to detect group differences. Increasing the sample size by one would have brought 


































Figure 5. Behavioral deficits in mice infected with WEEV and dopaminergic neuron counts in 
the substantia nigra. Mice were placed in trackway shown in (A) and foot pads were tracked as 
mice moved towards their home cage. The time between paw swings (A), the duration until mice 
reached their home cage (C), and (D) the speed at which paws moved—once swing was 
initiated—was quantified using MATLAB software. Representative images of dopaminergic 
neuron staining in (F), and quantifications in (G). * = p<0.05, ** = p<0.01, *** = p<0.001. 
 
 
Alpha-synuclein aggregation during WEEV infection in wild-type and IKK2 KO mice 
 
A major clinical feature of Parkinson’s Disease is the presence of alpha-synuclein 
aggregates in the brain. These aggregates are phosphorylated at the S129 residue and are 
resistant to digestion by proteinase K. Phosphorylated-alpha synuclein is being investigated as an 
early biomarker of PD [62], and thus demonstrating the presence of these aggregates is critical in 
establishing an animal model to study the disease [15]. 
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Alpha-synuclein aggregation during WEEV infection was monitored by 
immunofluorescent staining of the P129 residue. Stained sections were evaluated blinded using a 
previously validated pathological scoring method [37]. Briefly, a the blinded researcher was 
asked to score the presence of aggregates in selective regions on a 1-5 scale (1 = no P129+ 
aggregates or cells, 2 = few/sparse aggregates with less than three cells, 3 = multiple aggregates 
with no more than 10 cells, 4 = dense aggregates with more than 10 P129+ cells, 5 = very dense 
aggregates with more than 20 cells). 
WEEV infection in mice has been shown to induce aggregation of PK-resistant P129 
alpha-synuclein [1]. This finding was replicated in all three regions (SN, hippocampus, cortex) 
examined in the current study (Fig. 6F-H, p<0.001). Moreover, the severity of these aggregates 
was found to be significantly reduced in the IKK2 KO mice compared to wild-type in all three 
regions; however, when comparing the KO/H2O/WEEV condition to the wild-type control, 
aggregate levels in the cortex (p=0.001) and hippocampus (p<0.001) were only partially rescued 
by the knock-out. KO/Mn/WEEV aggregates were significantly higher than KO/H2O/WEEV in 
the SN (p=0.02), but not in cortex or hippocampus (Fig. 6). The effect of the knockout on the 
Mn/WEEV dual treatment in wild-type could not be evaluated due to survivability of mice in 






Figure 6. Alpha synuclein aggregation during WEEV infection in wild-type and IKK2 KO mice. 
Alpha synuclein aggregation was assessed by whole brain immunofluorescent staining in wild- 
type and IKK2 KO mice (A-E). Aggregates were scored blinded on a scale of 1-5 and quantified 
in selective regions; the substantia nigra (F), hippocampus (G), and cortex (H). * = p<0.05, ** = 
p<0.01, *** = p<0.001. 
 
 
Selective loss of dopaminergic neurons in the substantia nigra 
 
A hallmark of Parkinsonian diseases is the loss of dopaminergic neurons in the substantia 
nigra, with the population of neurons in the substantia nigra pars reticulata being at the most risk. 
Loss of these neurons was evaluated by immunofluorescent staining in serial sections that 
spanned the nigral regions. Neurons were counted for positive fluorescence in regions of interest, 
and total neuronal counts were estimated based the width of the sections, the number of sections 
counted, and the distance between each section; volumetric counts were adapted from a 
previously described method [69]. No differences were detected between wt/control and 
wt/WEEV mice (representative section images in Fig. 5F). No mice in the wt/Mn/WEEV 
treatment group survived at the 8-week time point, so no comparisons were able to be made (Fig 
5G). These tests were slightly underpowered, for the high variability in neuronal counts within 
animals and the relatively small mean differences between groups would require a sample size of 







This study successfully demonstrates the validity of the multiple-hit model of Parkinson’s 
disease, and while this model has been described in prior studies [32, 43], it is unique in that it 
captures multiple facets of disease pathology; namely, neuroinflammation, alpha-synuclein 
aggregates, and motor deficits. While it has been demonstrated that WEEV can produce a 
parkinsonian phenotype, it was unknown of the effect can be enhanced by a second 
environmental insult—an accurate representation of PD etiology. Adding the novelty and 
physiological relevance of this model, this study demonstrates that this multi-hit potentiation of 
PD is partially mediated by neuroinflammatory signaling in astrocytes. However, the significant 
loss of animals in the wt/Mn/WEEV experimental group leaves the interpretation of such effects 
ambiguous. Furthermore, while the genetic knockout of IKK2 was found to be protective in 
regard to viral spread, and astrogliosis, and motor impairments, the knockout did not fully 
protect against the development of alpha-synuclein aggregates or the loss of dopaminergic 
neurons—in fact showing a baseline effect of neuronal loss. While there is a strong body of 
literature suggesting that genetic knockout of IKK2 can have a protective effect in models of 
neurodegeneration [22, 26, 38], it has also been suggested that timing of NF-κB 
activation/inactivation is critical in modulating the progression and severity of disease states 
[11]. Future studies would benefit from inducible transgenic manipulation of NF-κB signaling. 
Another future direction to consider is the interaction of these environmental risk factors 
and genetic risk factors. To further elucidate the contribution of neuroinflammation to disease 
pathogenesis, it is necessary to manipulation inflammatory signaling in the CNS using transgenic 
models that contain PG genetic risk factors. It would be interesting to examine if a PD phenotype 
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observed in genetic models is rescued by dampening inflammatory signaling, and if this effect 
can be reversed by including an inflammatory environmental risk factor. Lastly, this study used 
the IKK2 KO as a means of knocking out NF-κB driven inflammation in glial cells, but we did 
not consider other targets of IKK2. It has been shown that LRRK2 is a target of IKK2, and that 
phosphorylation of LRRK2 increases its own kinase activity—which leads to a PD disease state. 
Perhaps IKK2 is relevant to PD over and above its function in IκBα phosphorylation. 
Perhaps the most striking observation within the current study is the dramatic loss of 
animals in the wild-type Mn/WEEV condition. While the loss prevented further analysis from 
determining whether the increased mortality was paired with increased neuronal inflammation, 
selective neuronal loss, or presence of insoluble protein aggregates, it is clear these mice were 
protected by the modulation of NF-κB signaling in astrocytes, possibly though similar 
mechanisms by which the WEEV treatment group was protected against the aforementioned 
pathological hallmarks. An alternative explanation that is unrelated to the pathophysiology of PD 
is that inhibiting NF-κB signaling increases the efficacy of the adjunct immunotherapy 
administered during WEEV infection. As previously discussed, WEEV infection is highly lethal 
in wild-type mice [35] without immunotherapy. Astrocyte-derived cytokines—both pro and anti- 
inflammatory—play an important role in blood-brain barrier integrity, CNS macrophage 
reactivity, and recruitment of peripheral macrophages from the bloodstream [7, 28]. Perhaps 
subtle changes in NF-κB-dependent cytokine expression in astrocytes have global impacts on 
macrophage activity in the central and peripheral systems. 
Despite the lack of data in the wild-type Mn/WEEV group, this study sheds light on the 
role of astrocyte-derived neuroinflammation in the development of Parkinson’s disease. We have 
shown that the combination of manganese and WEEV results in increased severity of subsequent 
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neuroinflammatory responses that persists eight weeks after infection. Furthermore, either in 
conjunction with, or as a result of this neuroinflammatory model, mice developed aggregated of 
alpha-synuclein in the substantia nigra, hippocampus, and several cortical regions and displayed 
motor impairments similar to those of Parkinson’s disease. In support of the hypothesis that these 
parkinsonian features are caused by glial-derived neuroinflammation, knocking out a key 
regulator of neuroinflammation in astrocytes ameliorated many of these effects. Together, these 
data lend further support to glial-derived neuroinflammation as a causative rather than 







DsRed and firefly Luciferase recombinant WEEV constructs 
 
The subgenomic promoter (SGP) sequence (nucleotides 7341–7500 of viral genome) of WEEV 
McMillan strain was duplicated to express DsRed and Firefly luciferase. Plasmids were purified 
using the QIAprep Spin MiniPrep Kit (Qiagen, Valencia, CA USA) and subsequently transcribed 
using T7 RNA polymerase (MAXIscript™ kit, Life Technologies, Grand Island, NY USA). 
Recombinant plasmids were then transfected with 20 µL of total RNA using an ECM 630 
electroporator (BTX Harvard Apparatus, Holliston, MA USA) in BHK-21cells (2×107 in 400 
µL). After transfection, virus was collected and stored at −80°C before quantification of viral 
concentration with plaque assays. 
Generation of astrocyte-specific knockout mice 
 
Astrocyte specific knockout mice for IKK2 were generated as previously described [37]. Briefly, 
hGfap-cre+/- (Cat#: 004600; Jackson Laboratories) mice were backcrossed on a C57/BlJ6 
background for twelve generations before crossbreeding with Ikk2-loxP+/+mice. Four generations 
of crossbreeding were conducted to acquire hGfap-cre+/-/Ikk2-loxP+/+ (KO). Littermates lacking 
Cre recombinase (hGfap-cre-/-/Ikk2-loxP+/+) were used as genotype controls for the study. 
Viral infections and manganese chloride treatment regimen in control and transgenic mice. 
 
Procedures were approved by Colorado State University Institutional Animal Care and Use 
Committee (IACUC) and were conducted in compliance of National Institute of Health 
guidelines. Infected mice were housed in a biosafety level 3 (BSL-3) facility at the Infectious 
Disease Research Center on the campus of Colorado State University. C57BL/6 astrocyte- 
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specific knockout mice (Gfap -Cre+/- mice with Ikk2-loxP+/+) and control mice (Gfap -Cre-/- mice 
with Ikk2-loxP+/+) were housed on a 12 hr light/dark cycle in a temperature-controlled room 
(maintained at 22-24°C). At day P21, mice were administered MnCl2 (50mg/kg/day) or normal 
drinking water by monitoring water intake and weight gain for 30 days. At P51 mice were placed 
back on regular drinking water and intranasally administered WEEV-DsRed, WEEV-Luc, or 
saline. Infections with recombinant WEEV were performed as previously described [9]. Mice 
were anesthetized with isoflurane (Minrad Inc, Bethlehem, PA USA) in an XGI-8 anesthesia 
system (Caliper Life Sciences, Waltham, MA USA) and imaged using an IVIS 200 (Caliper Life 
Sciences, Waltham, MA USA) bioluminescence imaging system. Lightly anesthetized mice were 
then administered 20 µL dropwise on the nostrils of either DsRed-WEEV or Luc-WEEV at a 
concentration of 1×104 PFU/ml. All mice infected with Luc-WEEV received a subcutaneous 
administration of luciferin at a dose of 150 mg/kg, 10-15 minutes prior to imaging on an IVIS 
imager. For background subtractions, uninfected mice were used as image controls. All mice 
were imaged on the same exposure time at 2 minutes, under standard settings for the IVIS 200 
camera. Image analysis was performed on Living Image 3.0 software (Caliper Life Sciences, 
Waltham, MA USA). Total light emission from each mouse was determined by creating a region 
of interest (ROI) of standard size for each mouse and collecting light emission data. Infected 
mice and control mice received an anti-E1 therapy intraperitoneally at 12 and 48hrs post- 
infection. 
Tissue preparation and sectioning 
 
Ten-day and eight-week post-infection with Luc-WEEV, animals were terminally anesthetized 
with isoflurane and transcardially perfused. The brains were then extracted, fixed in 3% 
paraformaldehyde at 4°C and later processed for paraffin embedding and sectioning at 8 microns. 
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Immunofluorescent Staining and Imaging 
 
Sections were paraffin embedded and mounted on glass slides and stored at room temperature 
away from light. Prior to staining, sections were deparaffinized using a Leica Bond RXM 
automated robotic staining system. Tissue was permeabilized using Bond Epitope Retrieval 
Solution for 30 minutes and incubated with primary antibody for one-hour (anti-tyrosine 
hydroxylase (TH; 1:500; Millipore AB152), anti-glial fibrillary acidic protein (GFAP; 1:500; 
DAKO Z0334), anti-serine phosphorylated 129 (p129; 1:100; WAKO pSYN#64). Antibodies 
were diluted according to manufacturer’s recommendations in TBS and 0.01% TX-100. Sections 
were washed in antibody dilution buffer 3 time prior to secondary antibody incubation, which 
was performed at room temperature for 1 hour. Slides were then coverslipped using ProLong™ 
Gold Antifade Mountant with DAPI (ThermoFischer P36931) and stored at room temperature 
away from light until imaging. DsRed-WEEV tissue was prepared similarly without antibody 
incubation or nuclear counterstaining. Sections were imaged using a Hammatsu Flash4.0 digital 
CMOS camera, ProScan III stage controller (Prior, Rockland, MA USA) and CellSens 
Dimension software (version 1.12, Olympus, Center Valley, PA, USA). 
Behavioral Analysis 
 
Following previously established protocols, mice were acclimated to handling, and the gain 
analysis trackway two weeks before infections [16, 42]. Baseline measurements were taken one 
day before infections with WEEV. As previously described, multiple neurobehavioral 
parameters, including, run duration, swing speed, swing time, and paw support were measured 
using a real-time video gait analysis system [17]. All behavioral testing was performed on 
uninfected and infected mice on days 0 and 56. All parameter values were normalized by 
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subtracting from the baseline measurements obtained on day 0 to normalize across all time points 
and treatment groups. 
Statistical Analysis 
 
All statistical analyses were performed using GraphPrism (version 9.0.0, Graph Pad Software, 
San Diego, CA) and SigmaPlot (version 14.5, Systat Software, San Jose, CA). All data points 
were assessed for outliers using ROUT (α=1%), and outliers were excluded from analyses. 
Group comparisons were analyzed by one-way ANOVA and post-hoc pairwise Tukey tests. 
Significant was defined as p<0.05. Power analysis was performed using SigmaPlot. All reported 
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